"Where Everyone Has an MBA"
Tel: (612) 246-4616
Frequently Asked Questions
- Frequently Asked Questions
- User Testimonials
Aduro BioTech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aduro BioTech Inc
East Bay cancer drug developer, jilted by Novartis, to cut 51 jobs
- Jan 10th, 2020 11:03 pm
Biotechs punch up talking points leading into big Union Square conference
- Jan 10th, 2020 11:00 pm
Aduro Biotech Announces Corporate Restructuring
- Jan 9th, 2020 9:15 pm
Hedge Funds Are Betting On Aduro BioTech Inc (ADRO)
- Dec 14th, 2019 10:18 pm
Does Aduro BioTech, Inc. (NASDAQ:ADRO) Have A Volatile Share Price?
- Dec 9th, 2019 10:06 am
Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?
- Dec 7th, 2019 4:31 pm
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting
- Nov 8th, 2019 9:05 pm
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
- Nov 8th, 2019 5:20 pm
Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2019 12:35 am
Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results
- Nov 7th, 2019 9:05 pm
Should You Worry About Aduro BioTech, Inc.'s (NASDAQ:ADRO) CEO Pay?
- Oct 25th, 2019 11:49 am
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
- Oct 2nd, 2019 8:05 pm
Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
- Sep 30th, 2019 8:05 pm
Do Insiders Own Lots Of Shares In Aduro BioTech, Inc. (NASDAQ:ADRO)?
- Sep 19th, 2019 1:49 pm
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Sep 4th, 2019 12:30 pm
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference
- Sep 3rd, 2019 8:05 pm
Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report?
- Aug 31st, 2019 1:31 pm
Who Has Been Selling Aduro BioTech, Inc. (NASDAQ:ADRO) Shares?
- Aug 14th, 2019 6:32 pm
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
- Aug 5th, 2019 2:46 pm
Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
- Aug 1st, 2019 8:05 pm
Frequently Asked Questions
Terms and Conditions
Copyright © 2020 VentureLine
Website developed by Digital Solutions